Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Tele 2 in the largest competition damages case in Sweden
Mandate

Vinge advised Tele 2 in the largest competition damages case in Sweden

May 27, 2016

Stockholm District Court delivered its judgment today in the largest competition damages case in Sweden to date.

According to the judgment, Telia shall pay damages in the amount of SEK 240 million plus interest to Tele2. The total damages awarded thus currently amounts to approximately SEK 500 million. Notice of appeal must be submitted to Svea Court of Appeal on or before 16 June 2016.

The case relates to damages for alleged abuse of a dominant position by Telia at the beginning of 2000. The alleged abuse consisted of so-called margin squeezing in connection with the provision of resale services for broadband connections via ADSL.

Vinge’s team consists of advokat Johna Karlsson (partner) and advokat Mikael Broomé as well as counsel Richard Westman and associate Karl Samuelsson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024